Lau J, Bloch P, Schäffer L, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem, 58(18):7370-80.
AnimalPMID 26308095DOI↩
GLP-1 agonist · 6 min read
The weekly shot (and now pill) behind Ozempic and Wegovy. It copies a gut hormone that curbs appetite, and large trials show it also protects the heart and kidneys and improves fatty liver disease.
Approved as Ozempic (type 2 diabetes, heart and kidney protection) and Wegovy (weight, heart risk, fatty liver disease). Compounded copies stopped being allowed after the shortage ended in 2025.
Not prohibited, but WADA is monitoring its use by athletes.
How well it has worked for me, from 1 to 10. One person's experience, not evidence, and not a recommendation or dosing advice.Read my experience →
Sources for these ratings are cited in the guide below, mainly in Legal status.
Semaglutide is a lab-made copy of GLP-1, a hormone your gut releases after you eat. Chemists changed two of its building blocks, one of them to protect it from being broken down, and attached a fatty-acid chain that clings to proteins in the blood. These changes help it last [1]: in people, it stays in the body for about a week [S1].
It’s one of the best-studied peptide medicines in the world. It’s sold as Ozempic for type 2 diabetes [S2] and as Wegovy for weight loss, heart protection and fatty liver disease [S1]. Wegovy comes as a weekly injection or a daily tablet [S1].
| What we know so far | What we still don’t know |
|---|---|
| It causes large, lasting weight loss while people keep taking it [3, 6] | How to keep weight off after stopping [7] |
| It lowers the risk of heart attack, stroke and kidney failure in high-risk people [8, 10] | How it affects strength and performance in fit, healthy people [16] |
| It improves fatty liver disease, knee pain and heart failure symptoms [11, 12, 13] | How much the eye condition seen in some studies is truly caused by the drug [18, 19] |
Semaglutide is a peptide success story. A small tweak to a natural gut hormone produced a medicine that, in large trials, helps people lose about 15% of their body weight and lowers the risk of heart attacks, strokes and kidney failure.
It isn’t magic, though. Stomach side effects are common, some of the weight lost is muscle, and most of the weight returns after stopping. For athletes, it isn’t banned in sport for now, but we found no studies of what it does for fit, healthy people. The safest route is the approved product, prescribed and monitored by a clinician.
Peer-reviewed sources indexed in PubMed, numbered in order of first citation. Study type is shown so you can judge how directly each source applies to humans.
Lau J, Bloch P, Schäffer L, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem, 58(18):7370-80.
AnimalPMID 26308095DOI↩
Friedrichsen M, Breitschaft A, Tadayon S, et al. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab, 23(3):754-762.
Human RCTPMID 33269530DOIFree full text↩
Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 384(11):989-1002.
Human RCTPMID 33567185DOI↩
Wharton S, Freitas P, Hjelmesæth J, et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol, 13(11):949-963.
Human RCTPMID 40961952DOI↩
Wharton S, Lingvay I, Bogdanski P, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med, 393(11):1077-1087.
Human RCTPMID 40934115DOI↩
Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14):1414-1425.
Human RCTPMID 33755728DOIFree full text↩
Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab, 24(8):1553-1564.
Human RCTPMID 35441470DOIFree full text↩
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med, 389(24):2221-2232.
Human RCTPMID 37952131DOI↩
Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 375(19):1834-1844.
Human RCTPMID 27633186DOI↩
Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med, 391(2):109-121.
Human RCTPMID 38785209DOI↩
Sanyal AJ, Newsome PN, Kliers I, et al. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med, 392(21):2089-2099.
Human RCTPMID 40305708DOI↩
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med, 389(12):1069-1084.
Human RCTPMID 37622681DOI↩
Bliddal H, Bays H, Czernichow S, et al. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med, 391(17):1573-1583.
Human RCTPMID 39476339DOI↩
Bonaca MP, Catarig AM, Houlind K, et al. (2025). Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet, 405(10489):1580-1593.
Human RCTPMID 40169145DOI↩
Cummings JL, Atri A, Sano M, et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet, 407(10544):2167-2179.
Human RCTPMID 41865758DOI↩
Batsis JA, Gavras A, Gross DC, et al. (2026). Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. Ann Intern Med, 179(7):996-1013.
Systematic reviewPMID 41996180DOI↩
Hjelmesæth J, Bhat S, Garvey WT, et al. (2026). Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes Obes Metab.
Human RCTPMID 42764399DOI↩
Hathaway JT, Shah MP, Hathaway DB, et al. (2024). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol, 142(8):732-739.
Human observationalPMID 38958939DOIFree full text↩
Cai CX, Hribar M, Baxter S, et al. (2025). Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol, 143(4):304-314.
Human observationalPMID 39976940DOIFree full text↩
Wharton S, Calanna S, Davies M, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab, 24(1):94-105.
Human RCTPMID 34514682DOIFree full text↩
Galli M, Benenati S, Laudani C, et al. (2025). Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol, 86(20):1805-1819.
Systematic reviewPMID 40892610DOI↩
Wang W, Volkow ND, Berger NA, et al. (2024). Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med, 30(1):168-176.
Human observationalPMID 38182782DOIFree full text↩
Novo Nordisk, via U.S. National Library of Medicine (DailyMed). WEGOVY (semaglutide) injection and tablets: prescribing information (revised 06/2026). Accessed Nov 3, 2026.
Novo Nordisk, via U.S. National Library of Medicine (DailyMed). OZEMPIC (semaglutide) injection: prescribing information. Accessed Nov 3, 2026.
U.S. Anti-Doping Agency. Weight Loss Drugs: What Athletes Need to Know About GLP-1s. Accessed Nov 3, 2026.
World Anti-Doping Agency (copy hosted by the International Testing Agency). World Anti-Doping Code International Standard: Prohibited List 2026. Accessed Nov 3, 2026.
U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of Oct 1, 2026). Accessed Nov 3, 2026.
U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of Apr 1, 2026). Accessed Nov 3, 2026.
Free weekly email + Scorecard PDF
One short email every Friday: new research, FDA and anti-doping news, and scorecard changes. Subscribe and get the printable Peptide Evidence Scorecard free. Plain language, sources included. No sponsors, no vendor codes.